Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome is a severe adverse drug-induced hypersensitivity reaction. We report a case of DRESS syndrome in a 17-year-old female caused by itraconazole, confirmed by patch testing, that required treatment with both corticotherapy and cyclosporine. Our case highlights the importance of clinical suspicion of this syndrome in pediatric age and the novelty of an antifungal drug being identified as the culprit.
Get full access to this article
View all access options for this article.
References
1.
JevticD, DumicI, NordinT, et al.Less known gastrointestinal manifestations of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: A systematic review of the literature. J Clin Med, 2021; 10(18):4287.
2.
RadovanovicM, JevticD, CalvinAD, et al.“Heart in DRESS”: Cardiac manifestations, treatment and outcome of patients with drug reaction with eosinophilia and systemic symptoms syndrome: A systematic review. J Clin Med, 2022; 11(3):704.
3.
MoriF, CaffarelliC, CaimmiS, et al.Drug reaction with eosinophilia and systemic symptoms (DRESS) in children. Acta Biomed, 2019; 90(3-S):66–79.
4.
CalogiuriG, GarveyLH, NettisE, et al.Skin allergy to azole antifungal agents for systemic use: A review of the literature. Recent Pat Inflamm Allergy Drug Discov, 2019; 13(2):144–157.
5.
CalleAM, AguirreN, ArdilaJC, et al.DRESS syndrome: A literature review and treatment algorithm. World Allergy Organ J, 2023; 16(3):100673.
6.
MiyagawaF, AsadaH. Current perspective regarding the immunopathogenesis of drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS). Int J Mol Sci, 2021; 22(4):2147.
7.
CardonesAR. Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. Clin Dermatol, 2020; 38(6):702–711.
8.
MasseyJ, KumarK, NgK, et al.Skeletal myositis as the sole feature of relapsing drug reaction with eosinophilia and systemic symptoms syndrome. Ann Allergy Asthma Immunol, 2017; 118(6):726–728.
9.
HusainZ, ReddyBY, SchwartzRA. DRESS syndrome: Part II. Management therapeutics. J Am Acad Dermatol, 2013; 68:709.e1–709.e9.
TanK, TestroA. Cyclosporine as an alternative immunosuppressant for steroid-resistant drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome. BMJ Case Rep, 2023; 16(3):e250983.
12.
BarbaudA, CastagnaJ, SoriaA. Skin tests in the work-up of cutaneous adverse drug reactions: A review and update. Contact Derm, 2022; 86(5):344–356.
13.
BergmannMM, CaubetJC. Role of in vivo and in vitro tests in the diagnosis of severe cutaneous adverse reactions (SCAR) to drug. Curr Pharm Des, 2019; 25(36):3872–3880.
14.
WeirC, LiJ, FultonR, et al.Development and initial validation of a modified lymphocyte transformation test (LTT) assay in patients with DRESS and AGEP. Allergy Asthma Clin Immunol, 2022; 18(1):90.
15.
CabañasR, CalderónO, RamírezE, et al.Sensitivity and specificity of the lymphocyte transformation test in drug reaction with eosinophilia and systemic symptoms causality assessment. Clin Exp Allergy, 2018; 48(3):325–333.
